Wilmington Savings Fund Society’s MoonLake Immunotherapeutics MLTX Stock Holding History

Wilmington Savings Fund Society’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175	Buy	+9	New	+$163	﹤0.01%	1474

Other funds holding MLTX

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Wilmington Savings Fund Society's MLTX Position: Q2 2026 in Review

Wilmington Savings Fund Society opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 9 shares worth $175. The stake represents ﹤0.01% of the portfolio and ranks #1474 among its holdings.

15 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Wilmington Savings Fund Society held 9 shares of MoonLake Immunotherapeutics worth $175 as of Q2 2026.
MoonLake Immunotherapeutics was a new Wilmington Savings Fund Society position in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Wilmington Savings Fund Society's portfolio in Q2 2026, its #1474 holding.
15 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2026, filed 28 Jul 2026.